Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab

165Citations
Citations of this article
260Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Regulatory approval for a biosimilar product is provided on the basis of its comparability to an originator product. A thorough physicochemical and functional comparability exercise is a key element in demonstrating biosimilarity. Here we report the characterization of a proposed biosimilar rituximab (GP2013) and originator rituximab. Objective: To compare GP2013 with originator rituximab using an extensive array of routine analytical and extended characterization methods. Methods: Primary and higher order protein structures were analyzed using a variety of methods that included high-performance liquid chromatography electrospray ionization mass spectrometry (HPLC-ESI-MS), peptide mapping with UV and MS detection, circular dichroism (CD), Fourier transform infrared (FTIR) spectroscopy, hydrogen deuterium exchange (HDX) MS, 1D 1H nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography and differential scanning calorimetry (DSC). Charge and amino acid modifications were assessed using cation exchange chromatography (CEX) and peptide mapping using reversed-phase (RP) HPLC. Boronate affinity chromatography was used to determine the relative amount of glycation. Glycans were identified and quantified after 2-aminobenzamide (2-AB) labeling and separation using normal phase HPLC with fluorescence and MS detection, respectively. Glycan site occupancy was determined using reducing capillary electrophoresis with sodium dodecyl sulfate (CE-SDS). Size heterogeneity was determined using reducing and non-reducing CE-SDS, size exclusion chromatography (SEC) and asymmetric flow field flow fractionation (AF4). Biological characterization included a series of bioassays (in vitro target binding, antibody-dependent cell-mediated cytotoxicity [ADCC], complement-dependent cytotoxicity [CDC] and apoptosis) and surface plasmon resonance (SPR) Fc receptor binding assays. Results: Intact mass analysis of GP2013 and the heavy and light chains using RP HPLC-ESI-MS revealed the expected molecular mass of rituximab. The amino acid sequence was shown to be identical between GP2013 and the originator rituximab. Further sequence confirmation using RP-HPLC-UV/MS peptide mapping showed non-distinguishable chromatograms for Lys-C digested GP2013 and originator rituximab. The higher order structure of GP2013 was shown to be indistinguishable from originator rituximab using a large panel of redundant and orthogonal methods. GP2013 and originator rituximab were comparable with regard to charge variants, specific amino acid modifications and the glycan pattern. GP2013 was also shown to have similar purity, aggregate and particle levels when compared with the originator. Functionally, and by using a comprehensive set of bioassays and binding assays covering a broad range of rituximab's functional activities, GP2013 could not be distinguished from originator rituximab. Conclusion: GP2013 was shown to be physicochemically highly similar to originator rituximab at the level of primary and higher order structure, post-translational modifications and size variants. An extensive functional characterization package indicated that GP2013 has the same biological properties as originator rituximab. © 2013 The Author(s).

References Powered by Scopus

FcRn: The neonatal Fc receptor comes of age

1891Citations
N/AReaders
Get full text

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγrIIIa gene

1730Citations
N/AReaders
Get full text

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity

1553Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Chromatographic, Electrophoretic, and Mass Spectrometric Methods for the Analytical Characterization of Protein Biopharmaceuticals

227Citations
N/AReaders
Get full text

Physicochemical characterization of Remsima®

157Citations
N/AReaders
Get full text

Modern chromatographic and mass spectrometric techniques for protein biopharmaceutical characterization

149Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Visser, J., Feuerstein, I., Stangler, T., Schmiederer, T., Fritsch, C., & Schiestl, M. (2013). Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs, 27(5), 495–507. https://doi.org/10.1007/s40259-013-0036-3

Readers' Seniority

Tooltip

Researcher 79

48%

PhD / Post grad / Masters / Doc 73

45%

Professor / Associate Prof. 10

6%

Lecturer / Post doc 2

1%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 60

40%

Biochemistry, Genetics and Molecular Bi... 38

25%

Pharmacology, Toxicology and Pharmaceut... 33

22%

Chemistry 19

13%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free